FDA Approves Capivasertib Combo for PTEN-Deficient Prostate Cancer

SentiSense · Published · Updated

The FDA has approved a treatment combination for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer.

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis